Citation notice #9648 · 2026-08-11 06:34:47.152789+00:00

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab

Correction Crossref Open

cites Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial, which carries a correction notice dated 2011-08-03. One-hop deterministic notice: the citation edge exists in the Pith bibliography graph; no model judged whether the citation was load-bearing.

This is not a judgment on the citing paper.

Citing paper Event page Original DOI Notice DOI File a formal challenge All reference changes

01Evidence

Raw extraction · citation context · bibliography index 9

for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 2013; 31: 1719- 1725. 20130408. DOI: 10.1200/jco.2012.44.7912. 50. Robert NJ, Saleh MN, Paul D, et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial. Clin Breast Cancer 2011; 11: 82-92. 20110411. DOI: 10.1016/j.clbc.2011.03.005. 51. Martín M, Roche H, Pinter T, et al. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or 26 metastatic breast cancer: A phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 2011; 12: 369-376. 20110321. DOI: 10.1016/s1470-2045(11)70037-7.

Parser render (TeX stripped for reading; raw above is the evidence)

for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 2013; 31: 1719- 1725. 20130408. DOI: 10.1200/jco.2012.44.7912. 50. Robert NJ, Saleh MN, Paul D, et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial. Clin Breast Cancer 2011; 11: 82-92. 20110411. DOI: 10.1016/j.clbc.2011.03.005. 51. Martín M, Roche H, Pinter T, et al. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or 26 metastatic breast cancer: A phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 2011; 12: 369-376. 20110321. DOI: 10.1016/s1470-2045(11)70037-7

02Event

Type: Correction
Source: Crossref
Original DOI: 10.1016/j.clbc.2011.03.005
Notice DOI: 10.1016/j.clbc.2011.06.004
Date: 2011-08-03
Title: Erratum
Reasons: ['Erratum']
Work: Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial (2011)

Schema constants (for re-runners): correction · crossref

03Dispute this notice

If this citation does not depend on the flagged claim, or the event is wrong, say so. Disputes are public. For a signed challenge against the paper itself, use the formal challenge form.